Prospects for prevention of HPV-driven oropharynx cancer.

@article{Kreimer2014ProspectsFP,
  title={Prospects for prevention of HPV-driven oropharynx cancer.},
  author={A. Kreimer},
  journal={Oral oncology},
  year={2014},
  volume={50 6},
  pages={
          555-9
        }
}
Prevention of HPV-associated cancers can take two forms-one through prevention of infection via prophylactic HPV vaccination, and one through interruption of disease progression through early identification (i.e.: screening) and treatment. Primary prevention via vaccination seems promising, as a proof-of-principal study demonstrated high vaccine efficacy against one-time detection of oral HPV16/18 infection. In addition to the direct benefit of vaccination, indirect protection from reduced… Expand
Immunoprevention of Human Papillomavirus–Associated Malignancies
TLDR
Recent progress and opportunities to better prevent HPV-associated cancers are reviewed, including broadening immune protection to cover all hrHPV types, reducing the cost of HPV vaccines especially for developing countries that have the highest rates of cervical cancer, and immune-based treatment of established HPV infections. Expand
Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers.
TLDR
An overview on primary, secondary and tertiary prevention of HPV-driven OPC is provided and some directions for future research are discussed. Expand
Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer
TLDR
The future for developing novel and effective therapeutic agents for HPV-associated head and neck tumors is promising; continued progress is critical in order to meet the challenges posed by the growing epidemic. Expand
Human papillomavirus-related oropharyngeal cancer in the HIV-infected population.
TLDR
Although not demonstrated in randomized controlled trials, HPV vaccination may prevent oral HPV infection as well and the focus of organized HPV cancer prevention programs should include prophylactic HPV vaccination to reduce the burden of high-risk HPV and low- risk HPV types who have not yet been exposed. Expand
Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old).
TLDR
HPV vaccination appears to provide protection against vaccine-type oral HPV infection among males and females in the general population. Expand
Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature
  • J. Hirth
  • Medicine
  • Human vaccines & immunotherapeutics
  • 2019
TLDR
U uptake of the HPV vaccine remains modest, despite evidence that vaccine-type HPV prevalence is decreasing as a result of HPV vaccination, and geographic disparities in vaccination uptake across different US regions and by race/ethnicity may contribute to continuing disparities in HPV-related cancers. Expand
Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy
TLDR
A summary of the current understanding of HPV in head and neck cancer and the important advances that have shown HPV to be an etiological agent are discussed and the treatment options for patients with HPV-positive disease are likely to change in the future. Expand
Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study
TLDR
Prevalent oral HPV16 infections in men persisted longer than newly acquired infections, and persistence appeared to increase with age, which may explain the high prevalence of oral HPV observed at older ages. Expand
Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.
TLDR
This report summarizes the proceedings: a review of recent science on the descriptive epidemiology, etiology, biology, genetics, early detection, pathology and treatment of HPV-positive oropharyngeal cancer, and the formulation of key research questions to be addressed. Expand
Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study.
TLDR
HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
TLDR
Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age. Expand
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
TLDR
HPV prevalence four years after vaccination with the ASO4-adjuvanted HPV 16/18 vaccine was much lower among women in the vaccine arm compared to the control arm, suggesting that the vaccine affords strong protection against oral HPV16/18 infection, with potentially important implications for prevention of increasingly common HPV-associated oropharyngeal cancer. Expand
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
TLDR
The long-term efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) up to 8.4 y after the first vaccine dose was reported, and the safety profile was clinically acceptable for both vaccine and control groups. Expand
Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical Neoplasia
TLDR
There is promising data indicating that HPV mRNA and p16 might play an important role in future cervical cancer screening scenarios, still, large randomized studies are necessary to confirm the preliminary data. Expand
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
TLDR
End-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion, suggesting population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer. Expand
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study
TLDR
Acquisition of oral oncogenic HPV was significantly associated with smoking and not being married or cohabiting, but was similar across countries, age groups, and reported sexual behaviours. Expand
Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal “Pap-Test Equivalent” in High-Risk Populations
TLDR
Tonsillar HPV16 infection was not associated with atypical squamous cells of unknown significance (ASCUS), the only cytologic abnormality identified, and HPV16 was associated with OSCCs among individuals with accessible oropharyngeal lesions but not with cytologic evidence of dysplasia among high-risk individuals without such lesions. Expand
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
TLDR
In women positive for HPV DNA, HPV-16/18 vaccination does not accelerate clearance of the virus and should not be used to treat prevalent infections. Expand
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
TLDR
Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men and had a favorable safety profile and may help to reduce the risk of anal cancer. Expand
Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction
TLDR
There was a substantial decrease in vaccine-type HPV prevalence and evidence of herd protection in this community four years after licensing of the quadrivalent HPV vaccine. Expand
...
1
2
3
4
5
...